CJC-1295 No DAC — catalogued in the literature as Modified GRF (1-29) — is a 29-amino acid synthetic peptide derived from the N-terminal fragment of human growth hormone-releasing hormone (GHRH 1-44). Four targeted amino acid modifications at positions 2, 8, 15, and 27 confer resistance to enzymatic cleavage and extend circulating half-life relative to unmodified GRF (1-29). The DAC-conjugated variant was developed by ConjuChem Biotechnologies; the No DAC form isolates the core modified peptide without that albumin-binding moiety.

Published laboratory work has explored the compound’s interaction with GHRH receptors on pituitary somatotroph cells, downstream activation of adenylate cyclase, and the resulting modulation of cyclic AMP-dependent growth hormone synthesis and release. Preclinical rodent models have examined GH and IGF-1 secretion dynamics, body composition parameters, and effects on bone mineral density in GH-deficient states. All findings referenced here derive from preclinical models and have not been validated in controlled human clinical trials.

The most frequently cited pharmacokinetic data for the CJC-1295 class appears in The Journal of Clinical Endocrinology and Metabolism. CJC-1295 No DAC has not received approval from the U.S. Food and Drug Administration for any therapeutic indication and is not approved for human or veterinary use.